Dilazep inhibits binding of batrachotoxin to sodium channels in canine sarcolemmal vesicles.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Archives internationales de pharmacodynamie et de therapie

• Publication date

  1995-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 8861708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A study on dilazep: II. Dilazep attenuates lysophosphatidylcholine-induced mechanical and metabolic derangements in the isolated, working rat heart.

  1995cited by this paper
• A study on dilazep: I. Mechanism of anti-ischemic action of dilazep is not coronary vasodilation but decreased cardiac mechanical function in the isolated, working rat heart.

  1995cited by this paper
• The kinetics of [3H]SCH 23390 dissociation from rat striatal dopamine D1 receptors: effect of dopamine.

  1994cited by this paper
• Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels.

  1994cited by this paper
• Effects of antiischemic drugs on veratridine-induced hypercontracture in rat cardiac myocytes.

  1994cited by this paper
• Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle.

  1993cited by this paper
• Effects of dilazep in evolving myocardial infarction in dogs: a biochemical study.

  1989cited by this paper
• Class I antiarrhythmic drug receptor: biochemical evidence for state-dependent interaction with quinidine and lidocaine.

  1989cited by this paper
• Stereospecific interaction of tocainide with the cardiac sodium channel.

  1988cited by this paper
• Batrachotoxin: a window on the allosteric nature of the voltage-sensitive sodium channel.

  1988cited by this paper
• Mechanism of myocardial protective action of dilazep during ischaemia and reperfusion.

  1987cited by this paper
• A Receptor for Type I Antiarrhythmic Drugs Associated With Rat Cardiac Sodium Channels

  1987cited by this paper
• Effects of some antianginal and vasodilating drugs on sodium influx and on the binding of 3H-batrachotoxinin-A 20-α-benzoate and 3H-tetracaine

  1987cited by this paper
• Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels.

  1986cited by this paper
• Effect of dilazep on decrease in myocardial pH during ischemia in dogs.

  1986cited by this paper
• [3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.

  1985cited by this paper
• Batrachotoxin as a tool to study voltage-sensitive sodium channels of excitable membranes.

  1985cited by this paper
• Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by local anesthetics.

  1984cited by this paper
• Batrachotoxin-induced depolarization and [3H]batrachotoxinin-a 20 alpha-benzoate binding in a vesicular preparation from guinea pig cerebral cortex.

  1983cited by this paper
• Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles.

  1981cited by this paper
• Effects of coronary vasodilator drugs on the uptake and release of adenosine in cardiac cells.

  1979cited by this paper
• A simplification of the protein assay method of Lowry et al. which is more generally applicable.

  1977cited by this paper
• Activation of the action potential Na+ ionophore by neurotoxins. An allosteric model.

  1977cited by this paper

• K‐7259: A Cardioprotective Derivative of Dilazep

  2007cites this paper
• WIN 17317-3, a new high-affinity probe for voltage-gated sodium channels.

  1999cites this paper
• Beneficial effects of dilazep on the palmitoyl-L-carnitine-induced derangements in isolated, perfused rat heart: comparison with tetrodotoxin.

  1997cites this paper
• A new approach to the development of anti-ischemic drugs. Substances that counteract the deleterious effect of lysophosphatidylcholine on the heart.

  1997cites this paper